Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nabilone for PTSD Cue Reactivity
NCT03251326Phase 2Terminated
- Sponsor
- New York State Psychiatric Institute
- Start
- Oct 2015
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of nabilone in post-traumatic stress disorder (PTSD) and cannabis use disorder (CUD) (4 arms), sponsored by New York State Psychiatric Institute. Primary endpoint: Cue Reactivity (Emotional Stroop Task) at 1 month. Started Oct 2015; status: terminated.
02
Drugs
nabilone
03
Conditions
post-traumatic stress disorder (PTSD)cannabis use disorder (CUD)
Beyond the preview
Go deeper on NCT03251326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03251326.